Purchase this article with an account.
David E. Wang, John Awad, Blake Harp, Alice Chuang, Richard W. Yee; The Effectiveness Of Long Term Treatments For Meibomian Gland Dysfunction: A Retrospective Study. Invest. Ophthalmol. Vis. Sci. 2012;53(14):608.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Current treatments of MGD are aimed at unplugging the meibomian glands, altering meibum, and controlling inflammation on a short-term interval, typically days to weeks. Unfortunately, there has not been a comprehensive study evaluating the effectiveness of current collective treatments of MGD over longer intervals i.e. months to years. This study aims at taking the first step towards a longer-term comprehensive assessment of our current treatment approach of MGD.
A total of 82 patients were given a treatment regimen for both signs and symptoms of MGD. Efficacy of the treatments was assessed by basal tear test and ratings of 0-4 (0 = none, 4=severe) for anterior blepharitis, lid margin vascularity, MG obstruction and meibum turbidity for OS and OD. Baseline data were compared with follow-up data at 0-3 months, 3-6 months, 6-12 months and 1 year + using a paired t-test.
Statistically significant improvements were noted for anterior blepharitis and MG obstruction at all time points. Anterior blepharitis scores improved by 0.79 and 0.78 points in the 0-3 month group and 1.00 and 0.92 in the 3-6 month follow-up group OD and OS respectively. MG obstruction improved 0.68 in the lower left lid in the 0-3 month group at 1.43 and 1.86 points in the 1 year + follow-up group OD and OS respectively. In all cases there was no data indicating that the patients were getting worse on chronic treatment regimens.
This study shows that our current treatment approach of MGD do in fact have a positive impact on patients’ signs and symptoms.
This PDF is available to Subscribers Only